Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
8.67 USD | -3.02% | -2.91% | -0.86% |
05-31 | Bavarian Nordic Files for Supplemental US License for Smallpox-Monkeypox Vaccine | MT |
05-30 | Bavarian Nordic Gets $6.5 Million Funding for Development of Mpox Vaccine in Children | MT |
Sales 2024 * | 5.23B 755M 1.04B | Sales 2025 * | 5.05B 729M 1B | Capitalization | 14.07B 2.03B 2.79B |
---|---|---|---|---|---|
Net income 2024 * | 689M 99.44M 137M | Net income 2025 * | 947M 137M 188M | EV / Sales 2024 * | 2.69 x |
Net Debt 2024 * | 23.72M 3.42M 4.71M | Net cash position 2025 * | 849M 123M 169M | EV / Sales 2025 * | 2.62 x |
P/E ratio 2024 * |
20.3
x | P/E ratio 2025 * |
14.9
x | Employees | 1,381 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.85% |
Latest transcript on Bavarian Nordic A/S
1 day | -3.02% | ||
1 week | -2.91% | ||
Current month | -2.91% | ||
1 month | +13.11% | ||
3 months | +3.21% | ||
6 months | +5.35% | ||
Current year | -0.86% |
Managers | Title | Age | Since |
---|---|---|---|
Paul Chaplin
CEO | Chief Executive Officer | 57 | 98-12-31 |
Henrik Juuel
DFI | Director of Finance/CFO | 59 | 18-10-31 |
Russell Thirsk
COO | Chief Operating Officer | 56 | 22-03-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 73 | 10-04-26 | |
Director/Board Member | 57 | 22-12-31 | |
Frank Verwiel
BRD | Director/Board Member | 61 | 16-04-19 |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 8.67 | -3.02% | 14,284 |
24-06-06 | 8.94 | -0.56% | 6,553 |
24-06-05 | 8.99 | +1.93% | 7,438 |
24-06-04 | 8.82 | -1.13% | 196 |
24-06-03 | 8.921 | -0.10% | 1,105 |
Delayed Quote OTC Markets, June 07, 2024 at 01:48 pm
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+45.82% | 765B | |
-6.16% | 354B | |
+19.86% | 331B | |
+9.32% | 299B | |
+18.81% | 248B | |
-1.15% | 219B | |
+11.17% | 216B | |
+5.90% | 164B | |
-0.73% | 162B |
- Stock Market
- Equities
- BAVA Stock
- BVNRY Stock